• Usama Bin Zubair PIMS
  • Syed Azhar Ali CMH medical college Rawalakot, Pakistan
  • Rizwan Taj PIMS
  • Syeda Misbah Batool Alnafees


Background: The choice of the antipsychotic medication is based upon the risks, benefits and the cost. There has been still a debate that which group of antipsychotics is overall better amongst the two so we planned this study with the objective to compare the efficacy of the 1st & 2nd generation antipsychotics for the treatment of schizophrenia. Methods: This RCT was conducted at in/out patient department of Psychiatry at a tertiary care hospital of Pakistan over the time period of six months. All the patients of schizophrenia between 18–50 years of age of either gender and all the socioeconomic groups were included in the study. Each patient was assessed with the Simpson-Angus Scale (SAS) for the EPS and the Positive and Negative Syndrome Scale (PANSS) for the schizophrenia at the baseline, 6 weeks and 12 weeks after starting the designated medication. Results: The mean age of the 350 patients included in the study was 34.25±16.74 years. One hundred and forty-eight (42.3%) patients were female and 202 (57.7%) were male. The overall response of 1st Generation & 2nd Generation antipsychotics was 51 (140) 36% and 135 (210) 64% respectively (p-value=0.00024). Sixty-three (45%) patients who were taking 1st Generation Antipsychotics had relapse of the disease as compared to the 29 (13.7%) patients who were taking the 2nd Generation antipsychotics. Dryness of mouth, sedation and EPS were the common side effects with the 1st generation antipsychotics while dryness of mouth, cardiac arrhythmias, and sexual dysfunction were the common side effects with the 2nd generation antipsychotics. Conclusion: This study concluded that the 2nd generation antipsychotics were superior to the 1st generation antipsychotics among the patients of schizophrenia in terms of the success rate, relapse rate and the tolerability.Keywords: Effectiveness; Antipsychotics; Schizophrenia


Addington DE, Mohamed S, Rosenheck RA, Davis SM, Stroup TS, McEvoy JP, et al. Impact of second - generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. J Clin Psychiatry 2011;72(1):75–80.

National Collaborating Centre for Mental Health (Great Britain). Schizophrenia: full national clinical guideline on core interventions in primary and secondary care. London: Gaskell, Royal College of Psychiatrists: British Psychological Society; 2003.

Harvey RC, James AC, Shields GE. A systematic review and network meta-analysis to assess the relative efficacy of antipsychotics for the treatment of positive and negative symptoms in early-onset schizophrenia. CNS Drugs 2016;30(1):27–39.

Rehse M, Bartolovic M, Baum K, Richter D, Weisbrod M, Ely DR. Influence of Antipsychotic and Anticholinergic Loads on Cognitive Functions in Patients with Schizophreni. Schizophr Res Treatment 2016;2016:8213165.

Van Keating D, McWilliams S, Schneider I, Hynes C, Cousins G, Strawbridge J, et al. Pharmacological guidelines for schizophrenia: a systematic review and comparison of recommendations for the first episode. BMJ Open 2017;7:e013881.

Lally J, MacCabe JH. Antipsychotic medication in schizophrenia: a review. Br Med Bull 2015;114(1):169–79.

Crossley NA, Constante M, McGuire P, Power P. Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: meta-analysis. Br J Psychiatry 2010;196(6):434–9.

Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008;371(9618):1085–97.

Crespo-Facorro B, Pérez-Iglesias R, Mata I, Caseiro O, Martínez-Garcia O, Pardo G, et al. Relapse prevention and remission attainment in first-episode non-affective psychosis. A randomized, controlled 1-year follow-up comparison of haloperidol, risperidone and olanzapine. J Psychiatr Res 2011;45(6):763–9.

Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first- generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009;373(9657):31–41.

Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003;160:209–22.

Divac N, Prostran M, Jakovcevski I, Cerovac N. Second-Generation Antipsychotics and Extrapyramidal Adverse Effects. Biomed Res Int 2014;2014:656370.

Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013;382(9896):951–62.

Barnes TRE, Bhatti SF, Adroer R, Paton C. Screening for the metabolic side effects of antipsychotic medication: findings of a 6-year quality improvement programme in the UK. BMJ Open 2015;5(10):e007633.

Roohafza H, Khani A, Afshar H, Garakyaraghi M, Amirpour A, Ghodsi B. Lipid profile in Antipsychotic drug users: A comparative study. ARYA Atheroscler 2013;9(3):198–202.

Karslioglu EH, Ozalp E, Sahiner IV, Ozturk M, Albayrak MN, Aydin S, et al. Does Combined Antipsychotic Treatment Provide Better Control on Symptoms in Patients with Schizophrenia than the Monotherapy? Klin Psikofarmakol Bül-Bull Clin Psychopharmacol 2016;26(1):39–47.

Gupta S. First-generation vs second-generation antipsychotic drugs: The ongoing saga. Indian J Psychiatry 2010;52(1):23–77.

Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. Randomized Controlled Trial of the Effect on Quality of Life of Second- vs First-Generation Antipsychotic Drugs in Schizophrenia Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) FREE. Arch Gen Psychiatry 2006;63(10):1079–87.

Smith T, Weston C, Lieberman J. Schizophrenia (maintenance treatment). Am Fam Physician 2010;82:338–9.

Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010;36(1):71–93

Lieberman JA, Stroup TS. The NIMH-CATIE Schizophrenia Study: what did we learn? Am J Psychiatry 2011;168(8):770–5.

Reuler JB, Girard DE, Cooney TG. Current concepts. Wernicke’s encephalopathy. N Engl J Med 2011;18(16):1035–9.